News Briefing channel feed

Se­lec­ta turns to syn­bio play­er for $1.1B cap­sid deal; BioN­Tech signs $790M im­munother­a­py deal

4 years ago

So­sei and Ver­i­ly part­ner on GPCRs; Ob­sE­va touts PhI­II da­ta in en­dometrio­sis pain

4 years ago

An­nex­on shares fall 33% af­ter pa­tients drop out of Hunt­ing­ton's tri­al; Two Chi­nese biotechs net mod­est fi­nanc­ing rounds

4 years ago

As­traZeneca hands off epilep­sy pro­grams to Ovid; Amy­lyx scores pri­or­i­ty re­view for ALS drug 

4 years ago

Durect out-li­cens­es anal­gesic Posimir to Irish biotech in $136M deal; Ar­cutis gets 9-fig­ure loan to push for OK for pso­ri­a­sis cream

4 years ago

Boston start­up lands $28M, clos­es small biotech buy­out; New longevi­ty fund takes shape

4 years ago

Am­gen's Ote­zla bags ex­pand­ed FDA nod in pso­ri­a­sis; I-Mab CEO hits the ex­it amid shake­up at Chi­nese firm

4 years ago

Ab­b­Vie pe­ti­tions trade com­mis­sion to ban Alvotech's Hu­mi­ra biosim­i­lar; Cy­to­ki­net­ics li­cens­es heart drug to Chi­nese part­ner

4 years ago

Pur­due's mul­ti-bil­lion dol­lar set­tle­ment in jeop­ardy af­ter fed­er­al judge toss­es deal; Bio­Marin an­nounces glob­al gene ther­a­py col­lab­o­ra­tion

4 years ago

Oren­cia ap­proved by FDA for new in­di­ca­tion — graft vs host dis­ease; So­sei and Twist an­nounce an­ti­body dis­cov­ery deal

4 years ago

Keros gives Han­soh sub­sidiary li­cense for lead drug in $190M+ deal; Vac­citech snaps up new tools in small buy­out 

4 years ago

No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — claims suc­cess af­ter all

4 years ago

In­tel­lia dos­es first pa­tient with an­ti-HAE gene ther­a­py; So­bi an­nounces new R&D chief

4 years ago

To­tus pulls in $40M Se­ries A with sights on PI3Kα; FDA asks Sesen for an­oth­er tri­al af­ter CRL, biotech says

4 years ago

So­tio part­ners with Mer­ck to test lead can­di­date with Keytru­da; DC's KeifeRx rais­es $6M in Se­ries A — and brings on two new board mem­bers

4 years ago

vTv Ther­a­peu­tics cuts 65% of em­ploy­ees in shake­up; Freenome bags $300M in Se­ries D to ex­pand mul­ti­omics plat­form

4 years ago

Seat­tle biotech clos­es $18M Se­ries B — and ac­quires a com­pa­ny; An­oth­er George Church alum launch­es up­start

4 years ago

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

4 years ago
Cell/Gene Tx

Am­gen's Ote­zla notch­es an­oth­er PhI­II win; Califf earns ad­vo­ca­cy group­s' stamp of ap­proval

4 years ago

Can South Dako­ta's trans­genic cows help treat the flu?; A speedy re­view for Mer­ck­'s Pre­vnar ri­val in kids

4 years ago

Sci­wind gets li­cens­ing deal with Sanofi for meta­bol­ic dis­ease can­di­dates; Im­mu­ni­ty­Bio and En­Gene­IC reach deal for nano cell tech

4 years ago

Nev­er too late: For­bion pitch­es $100M SPAC; Kro­nos Bio re­leas­es ear­ly in­ter­im da­ta on CDK9 in­hibitor

4 years ago

Drag­on­fly gets Mer­ck on sec­ond TriN­KET can­di­date since 2018 col­lab; Chi­nese eye gene ther­a­py de­vel­op­er nabs $60M

4 years ago

Bio­gen pulls PRIME des­ig­na­tion for ad­u­canum­ab in Eu­rope; Mer­ck clos­es merg­er with Ac­celeron

4 years ago
First page Previous page 24252627282930 Next page Last page
A service from the Financial Times